The METABRIC consortium have reported somatic mutations in cBioPortal14 with co-reported detailed hormone receptor status, age at diagnosis (median age = 64 years for ER+ patients), mean follow up of >8 years, and disease-specific (breast-cancer-specific) outcome15,16. This evidence concerns the gene NR4A1 and breast cancer.